tradingkey.logo
tradingkey.logo
Search

Dianthus Therapeutics Inc

DNTH
Add to Watchlist
82.490USD
+0.600+0.73%
Close 06/18, 16:00ETQuotes delayed by 15 min
4.51BMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
9.00
Change
0
The current earnings forecast score of Dianthus Therapeutics Inc is 9.00, ranking 16 out of 389 in the Biotechnology & Medical Research industry. The average price target is 65.00, with a high of 100.00 and a low of 46.00.

Analyst Rating

Based on 16 analysts
Strong Buy
Current Rating
127.692
Target Price
+55.93%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Dianthus Therapeutics Inc
DNTH
16
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Dianthus Therapeutics Inc's expected revenue for the next quarter?

Dianthus Therapeutics Inc's expected revenue is 258.58K.

What is Dianthus Therapeutics Inc's price target?

Analysts forecast that Dianthus Therapeutics Inc's price target is USD 65.00, with the highest forecast at USD 100.00 and the lowest forecast at USD 46.00.

How have Dianthus Therapeutics IncDNTH's recent earnings per share performed?

The market expectation was USD -0.85, while Dianthus Therapeutics IncDNTH's earnings per share (EPS) for the previous quarter was USD -1.43. EPS for the next quarter is expected at USD -0.87.

What is the analyst rating for Dianthus Therapeutics Inc?

Based on the ratings of Dianthus Therapeutics Inc's stock from 16 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI